Summary
Background
Relatively few studies have examined the activity of alkylating agents in the treatment of advanced colorectal adenocarcinoma. Recent reports have suggested possible therapeutic activity for high-dose intravenous melphalan administered with autologous bone marrow transplantation (BMT) support. We conducted a phase II study to determine the efficacy of administering intravenous melphalan at doses that do not require BMT support in patients with advanced colorectal adenocarcinoma.
Patients and methods
Fifteen patients with histologically proven, bidimensionally measurable disease were treated. The starting dose of melphalan was 30 mg/m2, with dose escalation permitted.
Results
No objective responses were observed. Toxic effects were primarily reversible granulocytopenia and thrombocytopenia. There were no treatmentassociated deaths.
Conclusion
Melphalan's lack of efficacy at the doses administered does not disprove the steep chemotherapy dose-response relationship postulated for many solid tumors. However, we feel that it is unlikely that repetitive courses of high dose melphalan with autologous BMT support will be a practical approach to the management of advanced colorectal adenocarcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Einhorn LH: Improvements in fluorouracil chemotherapy? (editorial). J Clin Oncol 7:1377–1379, 1989
Erlichman C, Fine S, Wong A, Elhakim T: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469–475, 1988
Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailiard JA, Laurie JA, Tschetter LK, Wiesenfeld M: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407–1418, 1989
Valone FH, Friedman MA, Wittlinger PS, Drakes T, Eisenberg PD, Malec M, Hannigan JF, Brown BW Jr: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427–1436, 1989
Mayer RJ, Maclntyre JM, Steele GD Jr, Frei E: High-dose bolus 5-fluorourcil (5FU) for metastatic colorectal carcinoma (abstract 498). Proc Amer Soc Clin Oncol 2:127, 1983
Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study. J Clin Oncol 7:425–432, 1989
Schutt AJ, Hahn RG, Reitemeier RJ, Moertel CG: A phase 2 study of intermittent high-dose cyclophosphamide therapy of advanced gastrointestinal cancer. Cancer Res 33:2218–2220, 1973
Carter SK, Friedman M: Integration of chemotherapy into combination modality treatment of solid tumors. Cancer Treat Rev 1:111–129, 1974
Wasserman TH, Comis RL, Goldsmith M, Handelsman H, Penta JS, Slavik M, Soper WT, Carter SK: Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep 6:399–419, 1975
Leff RS, Thompson JM, Johnson DB, Mosley KR, Daly MB, Knight WA, Ruxer RL, Messerschmidt GL: Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma. J Clin Oncol 4:1586–1591, 1986
Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25–32, 1980
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Antman KH, Souhami RL: High-dose chemotherapy in solid tumors. Ann Oncol 4 (Suppl 1):S29-S44, 1993
Frei E: Antitumor agents — dose response curve: clinical and experimental considerations. Exp Hematol 7 (Suppl 5):262–264, 1979
Frei E, Canellos GP: Dose: a critical factor in cancer chemotherapy. Am J Med 69:585–594, 1980
Drewinko B, Yang LY, Ho DHW, Benvenuto J, Loo TL, Freireich EJ: Treatment of cultured human colon carcinoma cells with fluorinated pyrimidines. Cancer 45: 1144–1158, 1980
Corringham R, Gilmore M, Prentice HG, Boesen E: High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors. Cancer 52:1783–1787, 1983
Lazarus HM, Herzig RH, Graham-Pole J, Wolff SN, Phillips GL, Strandjard S, Hurd D, Forman W, Gordon EM, Coccia P, Gross S, Herzig GP: Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1:359–367, 1983
Carter SK: Integration of chemotherapy into combined modality treatment of solid tumors: II. Large bowel carcinoma. Cancer Treat Rev 1:111–129, 1974
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moore, D.F., Pazdur, R. & Abbruzzese, J.L. Phase II trial of intravenous melphalan in advanced colorectal carcinoma. Invest New Drugs 12, 133–136 (1994). https://doi.org/10.1007/BF00874443
Issue Date:
DOI: https://doi.org/10.1007/BF00874443